Literature DB >> 1567188

Recombinant alpha-2 interferon gel treatment of recurrent herpes genitalis.

M Lebwohl1, S Sacks, M Conant, J Connor, J M Douglas, L Eron, S Marlowe, J Mendelson, V Chen, P Bradstreet.   

Abstract

Topical recombinant alpha-2 interferon treatment of recurrent genital herpes was studied in a randomized, double-blind, placebo controlled clinical trial. Three hundred and eighty-seven patients were treated at eight study centers with either interferon gel or placebo four times daily for four days. Interferon therapy caused a 26% decrease in the duration of viral shedding. For male patients, there were also significant decreases in the time to crusting (17%) and duration of pain (34%) and itching (21%). For patients with recurrent genital herpes, treatment with topical interferon was found to be effective in decreasing the duration of viral shedding and, for males, pain, itching and time to crusting.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1567188     DOI: 10.1016/0166-3542(92)90044-6

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  2 in total

Review 1.  Current recommendations for the treatment of genital herpes.

Authors:  D T Leung; S L Sacks
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

2.  In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds.

Authors:  F Chen; K H Chan; Y Jiang; R Y T Kao; H T Lu; K W Fan; V C C Cheng; W H W Tsui; I F N Hung; T S W Lee; Y Guan; J S M Peiris; K Y Yuen
Journal:  J Clin Virol       Date:  2004-09       Impact factor: 3.168

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.